For the Quarter Ending December 2022
As per the data, Lisinopril prices across the United States market dropped around 3.6% during the fourth quarter of 2022 due to bearish demand from end-user pharmaceutical and healthcare industries coupled with adequate product availability among domestic retailers. The reason behind the accumulation was that domestic merchants had excessive imports from Asia as they had placed their orders in advance. In order to increase the inquiries from the end user sector and to clear their existing stockpiles, suppliers gradually reduced their quotations. All these factors combinedly resulted in a declining price trend in the US domestic market and with prices settled at around USD 319500/MT by the end of the quarter.
In the fourth quarter of 2022, the price trend for Lisinopril in the Asia Pacific market fluctuated. The market opened in October with bearish sentiments but enhanced in November, with prices settling at USD 297800/MT. The market supply side faced great uncertainty in the H1 of Q4, mainly due to the halt in production activities amid the Golden week holiday and Covid-19 restrictions. These factors caused an escalation in the prices of Lisinopril in November. Later, the upward trend declined in the last weeks of the quarter, with prices assembling at USD 289700/MT. Despite the ease in China's zero-COVID strategy in early December, the demand for Lisinopril was not improved throughout the month. Also, the trading activities were muted due to low inquiries from overseas buyers ahead of the year-end holidays.
During Q4 of 2022, the prices of Lisinopril resembled the trend of the Asia-Pacific region. The price of Lisinopril first decreased by 1.3% in October but later increased significantly by 2% in November, with values settling at USD 344200 /MT. In October, the lack of inquiries from the downstream pharmaceutical sector dampened the market sentiments for Lisinopril in the German domestic market. However, in the mid-quarter, the increment in Lisinopril prices was driven by low supply from Asian countries. Moreover, rising concerns about the economy and the high inflation rate in Europe impact the overall price of the product. Therefore, by the termination of Q4, the dynamics of the Lisinopril market were again suppressed as purchasing activities across the German domestic market dropped, with prices evaluated at USD 338750/MT.
For The Quarter Ending September 2022
In the North American region, the Lisinopril API price trend followed an upward trajectory in the third quarter of 2022. The United States market highlighted maintaining its dominance in the area on the back of the solid downstream demand from the pharmaceutical industry. However, the insufficient product availability in the domestic market because of unstable imports from China. Since China is a significant exporter of Lisinopril, the shutdown of a few production units for maintenance caused a low output, hindered supplies, and disrupted trading activities of the products. Therefore, the prices for Lisinopril API displayed a 3.2% increment by the end of the quarter, with values assembling at USD 331500/MT in the United States.
In the Asia Pacific region, the prices of Lisinopril API witnessed a positive sentiment in the market during the third quarter of 2022, backed by the increased downstream demand from various pharmaceutical and healthcare industries. Entering the quarter, the production rate of the Lisinopril API market was affected as China enacted a lockdown to manage the outbreak. Towards the H2 of the third quarter, the prices for Lisinopril API went higher due to the regional market supply shortage. However, after the markets reopened following the closure, the plants that manufacture Lisinopril underwent maintenance, resulting in a lack of inventories in the region. Therefore, the FOB Shanghai prices for Lisinopril API were assessed at USD 300000/MT in China at the end of the quarter with a quarterly inclination of 2.5%
With prices assembled at USD 332000/MT in July, the Lisinopril API's European market started in Q3 of 2022 on a declining note. As demand from the downstream food and pharmaceutical sector remained weak, most traders maintained a solid wait-and-see attitude. However, these values continued to improve until September and were settled at USD 341800/MT in Germany. The price rose for Lisinopril API was supported by a combination of factors, including a high demand from end users pharmaceutical, strong purchasing activity, and a lack of product availability in the German domestic market. Also, the situation in Europe worsened with ongoing lockdowns in Chinese ports and unrest in Russia and Ukraine.
In North America, the price trend for Lisinopril API followed a downward trajectory because of weak market sentiments in the second quarter of 2022. In terms of supply, there were sufficient inventories in the market, and suppliers were able to meet demand. China's economy continued to export more goods to the United States; despite the Covid suspension, but the ongoing supply bottleneck nonetheless constrained it. But decreased demand from downstream pharmaceutical industries in regional and overseas markets negatively impacted the Lisinopril market. In this quarter, the prices of Lisinopril decreased by a total of 5.1% compared to the previous quarter, with values evaluated at USD 321000/MT in June.
During Q2 2022, the Lisinopril API prices exhibited variation across the Asia Pacific region but remained lower than the previous quarter. With the onset of the quarter, a glimpse of beneficial market sentiments was flashed along with a 2.1% leap in price on account of increased demand in the regional market. The prices of Lisinopril API dropped drastically in May by 6.1% due to the resumption of lockdowns in significant manufacturing hubs, resulting in lower end-user demand and offtakes, which is the fundamental reason for Lisinopril's downward trend in China. As the country's major production centers remained shuttered, China's suspension and closure of factories and ports substantially impacted supply and demand projections in May. The shutdown of transportation and logistical networks affected product distribution and important international shipping ports across the country. Thus, by the quarter ending June, prices of Lisinopril API settled at USD 292500/MT in China.
During the second quarter of 2022, Lisinopril API showcased mixed sentiments in the European region due to oscillating demand fundamentals from the pharmaceutical and nutraceutical industries. The price trend of Lisinopril API fluctuated throughout the quarter with all the disruption going on across the European region. By the quarter's termination, the feeble trade market due to reduced export owing to lowering demand from the market resulted in the price declination of Lisinopril. Manufacturers were pessimist about the output, and the production level consistently fluctuated as the COVID-related restrictions in China also took a toll on both supply and demand in the domestic market. As a ripple effect in Germany, the CFR prices of Lisinopril API settled at USD 335000/MT in June.